Top Markets
Coin of the day
Novan, Inc. Novan, Inc.

Novan, Inc.

NOVN
Pozycja w akcjach #39525
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in... Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Cena akcji
$0.056
Ostatnia synchronizacja: 2023-08-21
Kapitalizacja rynkowa
$451.38K
Zmiana (1 dzień)
8.74%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Novan, Inc. (NOVN)

Kategoria

Historia stopy dywidendy dla Novan, Inc. (NOVN)
Stopa dywidendy (TTM) dla Novan, Inc. (symbol akcji: NOVN) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Novan, Inc. (NOVN) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji